Heterogeneity of reduced FEV1 in early adulthood: A looking forward, looking backwards analysis
Heterogeneity of Reduced FEV1 in Early Adulthood
Some individuals never achieve normal peak FEV1 in early adulthood. It is unknown if this is due to airflow limitation and/or lung restriction.
Methods for Investigating Reduced FEV1 in Early Adulthood
To investigate this, we:
- Looked forward in 19,791 participants in the Dutch Lifelines general population cohort aged 25-35 years with 5-year follow-up; and
- Looked backwards in 2032 participants in the Swedish BAMSE birth cohort with spirometry at 24 years of age but also at 16 and/or 8 years.
Key Findings on Reduced FEV1 from Lifelines and BAMSE Cohorts
- In Lifelines 8.5% of participants had reduced FEV1 at 25-35 years, 68% due to Preserved Ratio Impaired Spirometry (‘PRISm’) and 32% to airflow limitation (‘low-limited’); besides, 3.8% participants with normal FEV1 showed airflow-limitation (‘normal-limited’). Low-limited and normal-limited, but not PRISm, reported higher smoking exposures and asthma diagnosis than normal (p < 0.05). At 5-year follow-up, 91.2% of participants remained in the same group, and FEV1 decline was similar in normal and normal-limited participants, but statistically smaller (p < 0.05) in PRISm and low-limited;
- These observations were largely reproduced in BAMSE at 24 years of age; and,
- In BAMSE, low-limited or PRISm individuals were already identifiable at 8-16 years of age.
Conclusions obstained on Heterogeneity of reduced FEV1 in early adulthood
Low peak FEV1 in early adulthood is most often due to PRISm and results in a significant burden of respiratory symptoms. Only low-limited and normal-limited, but not PRISm, associate with a doctor diagnosis of asthma, and FEV1 decline was statistically different in PRISm indicating a need for differentiated clinical approaches. These spirometric abnormalities can be already identified in childhood and adolescence.
Authors
Nuria Olvera, Alvar Agusti, Judith M Vonk, Gang Wang, Jenny Hallberg, H Marike Boezen, Maarten van den Berge, Erik Melén, Rosa Faner
Read more details at
Fecha de publicación
2025 January 12
Categorías asociadas al artículo
Noticias relacionadas
Aging and Metabolic Changes in COPD Patients
Explore the metabolic changes in COPD patients, highlighting the influence of aging and sex, with pronounced effects in males. Discover how COPD affects protein metabolism and energy production, emphasizing early aging’s impact.
Association of a polygenic risk score for chronic obstructive pulmonary disease with lung function across the lifespan
Discover the strong associations between a polygenic risk score for COPD and lung function from childhood to elderly. Study includes individuals aged 4-84 years, revealing significant links from school age to elderly.
Bayesian modelling of combined FEV1 and FVC vital lung function trajectories: relationship with airflow obstruction and PRISm
Discover how Bayesian non-parametric trajectory modeling identified seven combined FEV1 and FVC life-course trajectories and their association with airflow obstruction (AO) and PRISm. Learn about the prevalence and onset age across trajectories based on the Framingham Offspring Cohort study.
Artículos
Lung function
- 759688· Prof Eric Melen et Al. – Lung-function trajectories: relevance and implementation in clinical practice.
- 769289·Caspar Schiffers, Rosa Faner, et al. Supranormal lung function: Prevalence, associated factors and clinical manifestations across the lifespan.
- 769491·Tamara Cruz, Núria Mendoza, Gema M Lledó, Lídia Perea, Núria Albacar, Alvar Agustí, Jacobo Sellares, Oriol Sibila, Rosa Faner. Persistence of a SARS-CoV-2 T-cell response in patients with long COVID and lung sequelae after COVID-19
- 769799·Alvar Agusti, Peter G. Gibson, Vanessa M. McDonald. Treatable Traits in Airway Disease: From Theory to Practice
- 778797· Xavier Alsina-Restoy, Rodrigo Torres-Castro, Yolanda Torralba García, Felip Burgos, Joan Albert Barberà, Àlvar Agustí, Isabel Blanco Does arterial oxygenation during exercise add prognostic value in pulmonary arterial hypertension?
Imagen desarrollada DALL·E y Canva